Mannose-binding lectin genotypes in leukemia patients and controls
| Mannose-binding lectin genotypes . | YA/YA andYA/XA . | YA/O andXA/XA . | XA/O and O/O . | O/O . |
|---|---|---|---|---|
| Controls | 145 (58) | 65 (26) | 40 (16) | 7 (2.8) |
| Leukemias* | 63 (46)† | 44 (32) | 30 (22) | 12 (8.8)† |
| Pre-B | 53 (47)† | 38 (34) | 22 (20) | 9 (8.0)† |
| T | 10 (42) | 6 (25) | 8 (33)† | 3 (12.5)† |
| t(12;21) positive | 14 (50) | 11 (39) | 3 (11) | 0 |
| t(12;21) negative* | 49 (45) | 33 (30) | 27 (25) | 12 (11)† |
| High hyperdiploid | 17 (55) | 9 (29) | 5 (16) | 2 (6.5) |
| High hyperdiploid or t(12;21) positive | 31 (53) | 20 (34) | 8 (14) | 2 (3.4) |
| Non-high hyperdiploid, t(12;21) negative* | 23 (41) | 18 (32) | 15 (27) | 5 (8.9)† |
| Standard or intermediate risk leukemia | 46 (48) | 30 (32) | 19 (20) | 9 (9.5)† |
| Higher risk leukemia* | 17 (41) | 14 (33) | 11 (26) | 3 (7.1) |
| Mannose-binding lectin genotypes . | YA/YA andYA/XA . | YA/O andXA/XA . | XA/O and O/O . | O/O . |
|---|---|---|---|---|
| Controls | 145 (58) | 65 (26) | 40 (16) | 7 (2.8) |
| Leukemias* | 63 (46)† | 44 (32) | 30 (22) | 12 (8.8)† |
| Pre-B | 53 (47)† | 38 (34) | 22 (20) | 9 (8.0)† |
| T | 10 (42) | 6 (25) | 8 (33)† | 3 (12.5)† |
| t(12;21) positive | 14 (50) | 11 (39) | 3 (11) | 0 |
| t(12;21) negative* | 49 (45) | 33 (30) | 27 (25) | 12 (11)† |
| High hyperdiploid | 17 (55) | 9 (29) | 5 (16) | 2 (6.5) |
| High hyperdiploid or t(12;21) positive | 31 (53) | 20 (34) | 8 (14) | 2 (3.4) |
| Non-high hyperdiploid, t(12;21) negative* | 23 (41) | 18 (32) | 15 (27) | 5 (8.9)† |
| Standard or intermediate risk leukemia | 46 (48) | 30 (32) | 19 (20) | 9 (9.5)† |
| Higher risk leukemia* | 17 (41) | 14 (33) | 11 (26) | 3 (7.1) |
Frequencies in percentage are given in parentheses. Pre-B/T = B-precursor or T-lineage acute lymphoblastic leukemia; t(12;21) = translocation t(12;21)(p13;q22).
P < .05 for the distribution of the mannose-binding genotype subgroups in cases and controls (trend analysis).
P < .05 for the frequency of the specific mannose-binding genotype subgroup in cases versus controls.